Document is current
Any future updates will be listed below
-
Authors
Rothwell, Erin https://orcid.org/0000-0002-2294-2299
Riches, Naomi O.
Johnson, Erin
Kaphingst, Kimberly A.
Kehoe, Kelsey
Jenkins, Sabrina Malone
Palmquist, Rachel
Torr, Carrie
Frost, Caren J.
Wong, Bob
Bonkowsky, Joshua L.
-
Funding
Funding for this research was provided by:
National Human Genome Research Institute (HG009037)
National Center for Advancing Translational Sciences (TR001597)
- License Information
-
More Information
Article History
Received: 29 March 2022
Accepted: 7 December 2022
First Online: 19 December 2022
Declarations
:
: Erin Rothwell has no conflicts of interest to disclose.Naomi O. Riches has no conflicts of interest to disclose.Erin Johnson, has no conflicts of interest to disclose.Kimberly A. Kaphingst has no conflicts of interest to disclose.Kelsey Kehoe, has no conflicts of interest to disclose.Sabrina Malone Jenkins has no conflicts of interest to disclose.Rachel Palmquist has no conflicts of interest to disclose.Carrie Torr has no conflicts of interest to disclose.Caren J. Frost has no conflicts of interest to disclose.Bob Wong has no conflicts of interest to disclose.Joshua L. Bonkowsky has been a consultant for Autobahn Therapeutics, Bluebird Bio, Calico, Enzyvant, Denali Therapeutics, Neurogene, and Passage Bio, is serving on the Board of Directors of wFluidx, holds stock options in Orchard Therapeutics, receives royalties from Manson Publishing and his spouse receives royalties from BioMerieux, and receives research support from NIH NINDS (5U54NS115052), NCATS as part of the Rare Disease Consortia Research Network; Vanishing White Matter Foundation.
